Cost Effectiveness of Sunitinib as First-Line Targeted Therapy for Metastatic Renal Cell Carcinoma in China
Nov 1, 2014, 00:00 AM
10.1016/j.jval.2014.08.2294
https://www.valueinhealthjournal.com/article/S1098-3015(14)04224-7/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1752
First Page :
A638
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04224-7&doi=10.1016/j.jval.2014.08.2294